WELCOME to epgonline.org

Welcome to epgonline.org, a free online source of credible and independent scientific content intended for healthcare professionals globally that brings all the medical information you need into one place, providing education and guidance to help with the diagnosis and treatment of your patients.

This website provides:

  • Drug information, categorised using the ATC Classification System, providing indication, dosage, administration and precautions.
  • Specialty and disease information, categorising specialties and diseases using the ICD-10 classification, with further insight found in the Disease Focus area.
  • The Horizons series of articles, written by our team of specialists, that ask what the future of healthcare holds, evaluating emerging trends to provide expert insight.
  • The latest news to keep you up-to-date with current advancements in drug development, advocacy and awareness, industry mergers and acquisitions, clinical trial progression and congress information.
  • Recent opinion articles shared with us by healthcare professionals to express their views and experiences.
  • A wide variety of accredited internal and external CME modules and courses, designed to educate on the latest care strategies for specific conditions.
  • The latest studies, trials and guidelines from global publications provide a comprehensive collection of current and past developments in medicine, helping you to provide best practice.
  • Medical applications that deliver creative solutions to aid in the diagnosis and treatment of your patients.
  • Specialist educational microsites, or Learning Zones, each devoted to self-directed medical education surrounding a specific disease, condition or procedure.

Registration is quick and simple, giving you unlimited access to all content and features, allowing you to save pages, comment on your favourite articles and access the personalised dashboard.

Search Drugs - A-Z

Latest News

Added 13 hours ago Drug news

First Phase III trial of sulopenem + probenecid versus ciprofloxacin to treat women with UTI infections.- Iterum Therapeutics.

Iterum Therapeutics plc , announced its initiation of the first of three Phase III clinical trials. In this trial, known...

Added 13 hours ago Drug news

Phase III FREEDOM-EV study shows Orenitram delays disease progression in pulmonary arterial hypertension patients- United Therapeutics

United Therapeutics Corporation announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram (treprostinil) extended-release tablets in patients...

Added 13 hours ago Drug news

Phase III ATLAS study success for two-drug regimen ,namely cabotegravir and rilpivirine, for the treatment of HIV compared with continuing a three-drug oral regimen. ViiV HealthCare + Janssen Therapeutics.

ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR)...


Alex Keen

EPAD – Changing the way we think about Alzheimer’s prevention

Posted 16 days ago

We spoke to Professor Craig Ritchie of the University of Edinburgh, the poject co-coordinator for EPAD, a collaborative venture that is facilitating meaningful progress in preventative Alzheimer’s therapies. Find out more about the project, its methods, expectations and goals.

Lauren McCracken

EAACI hot topics: Hereditary angioedema (HAE)

Posted 1 month ago

For many the fear of the unknown is a daunting thought, but particularly so for patients with HAE. Left untreated, this disease causes unpredictable recurrent severe swelling, typically of the limbs, face, intestinal tract and airway.

Alex Keen

EULAR 2018 – Biosimilars: the future of rheumatology?

Posted 2 months ago

EULAR's Annual European Congress of Rheumatology aims to encourage innovation and collaboration across all aspects of rheumatology, something that is particularly well illustrated by biologics and their more affordable counterpart, biosimilars. Could they unlock the door to accessible, life-changing treatment for millions more?